Just in Time From JACC: Survival After Implantable Cardioverter Defibrillator Therapy
Mehmet K. Aktas, MD, Associate Professor of Medicine, University of Rochester Medical Center, Rochester, NY
Interviewer: Gerald V. Naccarelli, MD, FACC,
Bernard Trabin Chair in Cardiology, Professor of Medicine, Chief Division of Cardiology, Associate Clinical Director Penn State Heart and Vascular Institute, Penn State University College of Medicine–Hershey, Hershey, PA
Correspondent: Zain Ul Abideen Asad, MD,
Assistant Professor of Medicine, Cardiovascular Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Study findings suggest that survival among patients with fast and dangerous heart rhythms who undergo implantable cardioverter defibrillator therapy is adversely affected by underlying mechanisms rather than by the shock therapy itself. Treatments focused on modifying the mechanisms that lead to fast and dangerous heart rhythms may improve survival in such patients.